Target Name: MIR6859-3
NCBI ID: G102465910
Review Report on MIR6859-3 Target / Biomarker Content of Review Report on MIR6859-3 Target / Biomarker
MIR6859-3
Other Name(s): microRNA 6859-3 | hsa-miR-6859-5p | microRNA mir-6859-3 | hsa-miR-6859-3p | hsa-mir-6859-3 | MicroRNA 6859-3

Understanding MIR6859-3: A Potential Drug Target and Biomarker

MicroRNA 6859-3 (MIR6859-3) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and function have made it an attractive target for researchers to study and develop new treatments.

MIR6859-3 is a small RNA molecule that contains only 19 amino acid residues. It is primarily expressed in the brain and is involved in the regulation of various cellular processes, including cell growth, differentiation, and survival. MIR6859-3 has been shown to play a role in the development and progression of several neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and schizophrenia.

One of the reasons why MIR6859-3 has generated so much interest is its unique structure. MIR6859-3 is a small RNA molecule that is composed of a single exon and a single splice leader. This makes it relatively simple and easy to study. Researchers have been able to use various techniques to study the molecular structure and function of MIR6859-3, including RNA sequencing, Southern blotting, and biochemical assays.

In addition to its unique structure, MIR6859-3 has also been shown to play a role in the regulation of cellular processes. Studies have shown that MIR6859-3 can interact with various cellular proteins, including the protein p21 (also known as CDK4), which plays a role in cell growth and survival. MIR6859-3 has also been shown to regulate the activity of the protein TrkB, which is involved in the transfer of signals from the cell surface to intracellular signaling pathways.

MIR6859-3 has also been shown to be involved in the development and progression of several neurological and psychiatric disorders. Studies have shown that MIR6859-3 is overexpressed in the brains of individuals with Alzheimer's disease and that it is involved in the development of neurodegeneration in the brain. Similarly, MIR6859-3 has also been shown to be involved in the development and progression of Parkinson's disease and in the regulation of the immune response.

Due to its unique structure and function, MIR6859-3 has generated a lot of interest among researchers as a potential drug target and biomarker. Studies have shown that MIR6859-3 can be effectively targeted with small molecules, including those that bind to specific MIR6859-3 binding sites. This has led to the development of several potential MIR6859-3-based drugs that are currently in clinical trials for the treatment of various neurological and psychiatric disorders.

In conclusion, MIR6859-3 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for several diseases. Its unique structure and function have made it an attractive target for researchers to study and develop new treatments. Further research is needed to fully understand the role of MIR6859-3 in the development and progression of these diseases, as well as its potential as a drug target and biomarker.

Protein Name: MicroRNA 6859-3

The "MIR6859-3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR6859-3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MIR6859-4 | MIR6860 | MIR6861 | MIR6862-1 | MIR6862-2 | MIR6863 | MIR6864 | MIR6865 | MIR6866 | MIR6867 | MIR6868 | MIR6869 | MIR6870 | MIR6871 | MIR6872 | MIR6873 | MIR6874 | MIR6875 | MIR6876 | MIR6877 | MIR6878 | MIR6879 | MIR6880 | MIR6881 | MIR6882 | MIR6883 | MIR6884 | MIR6885 | MIR6886 | MIR6887 | MIR6888 | MIR6889 | MIR6890 | MIR6891 | MIR6892 | MIR6893 | MIR6894 | MIR6895 | MIR7-1 | MIR7-2 | MIR7-3 | MIR7-3HG | MIR708 | MIR7106 | MIR7107 | MIR7108 | MIR7109 | MIR711 | MIR7110 | MIR7111 | MIR7112 | MIR7113 | MIR7114 | MIR7150 | MIR7151 | MIR7152 | MIR7153 | MIR7154 | MIR7155 | MIR7156 | MIR7158 | MIR7159 | MIR7160 | MIR7161 | MIR7162 | MIR718 | MIR720 | MIR744 | MIR7515 | MIR758 | MIR759 | MIR760 | MIR761 | MIR762 | MIR762HG | MIR764 | MIR765 | MIR766 | MIR767 | MIR769 | MIR770 | MIR7702 | MIR7703 | MIR7704 | MIR7705 | MIR7706 | MIR7843 | MIR7844 | MIR7845 | MIR7846 | MIR7847 | MIR7848 | MIR7849 | MIR7850 | MIR7851 | MIR7854 | MIR7855 | MIR7856 | MIR7974 | MIR7975